18:56 , Nov 16, 2018 |  BC Week In Review  |  Company News

ICER: asthma mAbs should be 50% cheaper for cost effectiveness

The Institute for Clinical and Economic Review (ICER) said the costs of five asthma mAbs would need to decrease by at least 50% to be cost effective in a final evidence report . ICER said...
17:57 , Sep 28, 2018 |  BC Week In Review  |  Company News

ICER finds asthma mAbs to be not cost-effective

In a draft evidence report , the Institute for Clinical and Economic Review (ICER) found that five biologics approved or in testing to treat asthma were not cost-effective compared with standard of care (SOC) therapies...
20:23 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Teva's subcutaneous reslizumab misses in Phase III for eosinophilic asthma

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) reported top-line data from a Phase III trial in 468 patients with uncontrolled asthma and elevated blood eosinophils of of >300 eosinophils per µL showing that 110 mg...
20:23 , Feb 2, 2018 |  BC Week In Review  |  Clinical News

Teva's subcutaneous reslizumab misses in Phase III for OCS-dependent asthma

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) reported top-line data from a Phase III trial in 177 patients with oral corticosteroid (OCS)-dependent asthma and elevated blood eosinophils showing that 110 mg subcutaneous reslizumab every four...
19:30 , Nov 15, 2017 |  BC Extra  |  Company News

FDA approves AZ's Fasenra for asthma

AstraZeneca plc (LSE:AZN; NYSE:AZN) said FDA approved Fasenra benralizumab as an add-on maintenance treatment in patients ages 12 and older with severe eosinophilic asthma. The pharma plans to launch the drug within the coming weeks...
00:58 , Jul 21, 2017 |  BC Week In Review  |  Company News

G-BA, NICE recommend Teva's Cinqaero in severe eosinophilic asthma

U.K.'s NICE issued a final appraisal determination (FAD) recommending the use of Cinqaero reslizumab from Teva Pharmaceutical Industries Ltd. (NYSE:TEVA; Tel Aviv:TEVA) to treat severe eosinophilic asthma. Teva said the decision was based on a...
00:53 , Dec 31, 2016 |  BioCentury  |  Finance

Delivering takeouts

  BioCentury’s 25th annual Buyside View finds biotech investors focusing on mid-cap names with late-stage or marketed products that could become M&A targets. “The main theme playing at the moment is investors like us are...
18:23 , Nov 18, 2016 |  BC Week In Review  |  Company News

Cinqaero sales and marketing update

The U.K.’s NICE said it needs additional information before it can recommend Cinqaero reslizumab from Teva as an add-on therapy for severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another drug for maintenance...
07:00 , Aug 22, 2016 |  BC Week In Review  |  Clinical News

Cinqaero reslizumab regulatory update

The European Commission approved Cinqaero reslizumab from Teva as an add-on therapy for severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus another drug for maintenance treatment. The company plans to launch the product...
07:00 , Jul 11, 2016 |  BC Week In Review  |  Clinical News

Cinqaero reslizumab regulatory update

EMA’s CHMP recommended approval of Cinqaero reslizumab from Teva as an add-on treatment for eosinophilic asthma. The company expects a decision from the European Commission on the MAA this half. Teva markets the humanized IL-5...